ACR 2017 Review

• Takeuchi T, Genovese MC, Haraoui B, et al. Dose Reduction of Baricitinib in Patients with Rheumatoid Arthritis
Achieving Sustained Disease Control: Results of a Prospective Study. Presented at: ACR; 3–8 November 2017, San
Diego. Abstract 1821.
• Taylor P, Galien R, Van der Aa A, et al. Monotherapy with Filgotinib, a JAK1-Selective Inhibitor, Reduces Disease-
Related Biomarkers in Rheumatoid Arthritis Patients. Presented at: ACR; 3–8 November 2017, San Diego. Abstract
504.
• Teitsma XM, Jacobs JWG, Welsing PMJ, et al. Effect of Treat-to-Target Tocilizumab- and Methotrexate-Based
Strategies on Health-Related Quality of Life in Newly Diagnosed Rheumatoid Arthritis Patients: Results of the U-Act-
Early Trial. Presented at: ACR; 3–8 November 2017, San Diego. Abstract 1476.
• Teitsma XM, Jaconbs JWG, Welsing PMJ, et al. Tocilizumab Inhibits Progression of Erosive Joint Damage in Early
Rheumatoid Arthritis More Effectively Than Step-up Methotrexate Therapy. Presented at: ACR; 3–8 November 2017,
San Diego. Abstract 2458.
• Tesser J, Gül A, Olech E, et al. Efficacy and Safety of Tofacitinib in Patients with Rheumatoid Arthritis and
Inadequate Response or Intolerance to Prior Therapies. Presented at: ACR; 3–8 November 2017, San Diego.
Abstract 2493.
• van der Heijde D, Gladman DD, FitzGerald O, et al. Tofacitinib Treatment in Patients with Psoriatic Arthritis and
Rates of Radiologic Progression According to Baseline CRP Levels: Results from a Phase 3 Clinical Study.
Presented at: ACR; 3–8 November 2017, San Diego. Abstract 880.
• van der Heijde D, Wollenhaupt J, Cohen SB, et al. Assessment of Radiographic Progression in Patients with
Rheumatoid Arthritis Treated with Tofacitinib: Data from an Open-Label Long-Term Extension Study over 3 Years.
Presented at: ACR; 3–8 November 2017, San Diego. Abstract 533.
• Weinblatt M, Genovese MC, Kremer J, et al. Assessment of Early Improvement in Pain and Other ACR Components
As Predictors for Achieving Low Disease Activity or Remission in Three Phase 3 Trials of RA Patients Treated with
Baricitinib. Presented at: ACR; 3–8 November 2017, San Diego. Abstract 499.
• Weinblatt M, Taylor C, Burmester GR, et al. Cardiovascular Safety during Treatment with Baricitinib in Rheumatoid
Arthritis. Presented at: ACR; 3–8 November 2017, San Diego. Abstract 2352.
• Westhovens R, Van der Aa A, Jamoul C, et al. Effect of Baseline MTX Dose on Clinical Efficacy and Safety in
Rheumatoid Arthritis Patients Treated with Filgotinib: Post-Hoc Analysis from a Phase 2B Study. Presented at: ACR;
3–8 November 2017, San Diego. Abstract 534.
• Winthrop K, Bingham CO, Bradley JD, et al. Evaluation of Pneumococcal and Tetanus Vaccine Responses in
Patients with Rheumatoid Arthritis Receiving Baricitinib: Results from a Long-Term Extension Trial Substudy.
Presented at: ACR; 3–8 November 2017, San Diego. Abstract 1824.
• Winthrop K, Lindsey S, Harigai M, et al. Tuberculosis, Potential Opportunistic Infections, and Other Infections of
Interest in Patients with Moderate to Severe Rheumatoid Arthritis in the Baricitinib Program. Presented at: ACR; 3–8
November 2017, San Diego. Abstract 2787.
• Winthrop K, Wouters A, Choy E, et al. The Effectiveness of Zoster Vaccine in RA Patients Subsequently Treated with
Tofacitinib. Presented at: ACR; 3–8 November 2017, San Diego. Abstract 1440.
• Wollenhaupt J, Silverfield J, Bong Lee E, et al. Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of
Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension Studies over 9 Years. Presented at:
ACR; 3–8 November 2017, San Diego. Abstract 522.
• Zamora N, Lopez-Olivio MA, Tayar J, et al. Comparative Effectiveness of Tofacitinib Versus Baricitinib in Rheumatoid
Arthritis Using a Systematic Review and Network Meta-Analysis of Randomized Trials. Presented at: ACR; 3–8
November 2017, San Diego. Abstract 531.